It appears that the biopharmaceutical industry is on its way to not only beat but completely demolish prior venture capital fundraising records, based on totals for the first half of 2020 reported in the quarterly Pitchbook-NVCA Venture Monitor, which shows that the biopharma sector raised $12bn during the first half of this year versus $17bn for all of 2019.
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
